Status:

COMPLETED

Pilot Clinical Investigation of Adaptative Eyeglasses for the Correction of Presbyopia

Lead Sponsor:

Laclaree

Collaborating Sponsors:

Iris Pharma

Conditions:

Presbyopia

Eligibility:

All Genders

Phase:

NA

Brief Summary

This study is a pilot clinical investigation of adaptive eyeglasses for the correction of presbyopia. The goal of this clinical investigation is to assess IMD safety and to obtain patient feedback on ...

Detailed Description

Presbyopia is a visual impairment caused by the normal aging of the eye lens and resulting in progressive loss of accommodation. As a consequence, from the onset of presbyopia occurring around 40-45 y...

Eligibility Criteria

Inclusion

  • Patient \>18 years of age, male or female who has given explicit informed consent (dated and signed)
  • Diagnosed with presbyopia
  • A wearer whose current corrective solution is a pair of progressive lenses that provide clear vision at both distance and near vision (worn at least 5 times per week for 4 hours per day), or, a wearer who has rejected progressive glasses that provide clear vision at both distance and near vision and who uses another corrective solution that provides clear vision at both distance and near vision (bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia)
  • Patient with a distance visual acuity of 10/10 at least with current corrective solution
  • Patient with a visual acuity of P2 at least in near vision with current corrective solution
  • Patient with at least 10/10 distance vision once corrected with contact lenses for the test
  • Inter-pupillary distance in distance vision between 55 and 71mm
  • Distance from temple-to-temple not exceeding 161mm
  • Addition greater than or equal to 1.75D: Add≥1.75D
  • Sphere strictly between -6D and +4D: -6D\<S\<+4D
  • Cylinder below 1.75D:C\<1.75D
  • Patient uses a computer (at least 3 times a week in private and/or work settings).
  • Affiliation to a social security scheme
  • French-speaking (fluent).
  • Patient willing to participate in the study.

Exclusion

  • Patient under tutorship or guardianship.
  • Patient unable to understand the study procedures and therefore to provide free and informed consent
  • Patient with reading difficulties
  • Patient with multifocal implants
  • Patient who has undergone multifocal surgery
  • Patient with prism correction
  • Patient with a current or past eye condition that may adversely affect vision
  • Patient being treated or having undergone surgery likely to adversely affect vision
  • Patient with mobility problems that would prevent tests and workshops from being carried out
  • Patient intolerant to wearing contact lenses for a few hours (only for presbyopes with ametropia)
  • Patient who is pregnant or breastfeeding
  • Patient already included once in the study
  • Patient placed in an institution based on a judicial or regulatory ruling, held in psychiatric department, in state-run prison, or employed by the study research sites or by the sponsor.

Key Trial Info

Start Date :

September 9 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 27 2022

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT05326607

Start Date

September 9 2021

End Date

January 27 2022

Last Update

April 13 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHU Saint-Etienne Hôpital Nord, Service d'Ophtalmologie 25, boulevard Pasteur

Saint-Etienne, France, 42055